Healthcare | April 20, 2026
New support group targets delayed diagnosis of Vasculitis in India
Originally established in Punjab, the Vasculitis Society of India is now expanding its footprint nationwide
Originally established in Punjab, the Vasculitis Society of India is now expanding its footprint nationwide
First launches expected in H1 2022
It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
Subscribe To Our Newsletter & Stay Updated
